A new role for p53 in maintaining genetic stability in embryonic stem cells

Cell Cycle

Volumn 4, Issue 3, 2005, Pages 363-364

  Xu, Yang ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cell cycle checkpoint; Differentiation; Genetic stability; p53; Self renewal

Indexed keywords

HOMEODOMAIN PROTEIN; NANOG; PROTEIN P53; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; BINDING SITE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL LINEAGE; CELL RENEWAL; DNA DAMAGE; ELIMINATION REACTION; EMBRYONIC STEM CELL; GENE MUTATION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC STABILITY; GERM CELL; HUMAN; PROGENY; PROMOTER REGION; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SOMATIC CELL; STEM CELL;

EID: 25444519775     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.3.1529     Document Type: Short Survey

References (17)

1. Sabapathy K, Klemm M, Jaenisch R, Wagner EF. Regulation of ES cell differentiation by functional and conformational modulation of p53. EMBO J 1997; 16:6217-29.
2. Aladjem MI, Spike BT, Rodewald LW, Hope TJ, Klemm M, Jaenisch R, Wahl GM. ES cells do not activate p53-dependent stress responses and undergo p53- independent apoptosis in response to DNA damage. Curr Biol 1998; 8:145-55.
3. 1 arrest and protection from apoptosis in embryonic stem cells after ionizing radiation. Proc Natl Acad Sci USA 2004; 101:14443-8.
4. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003; 113:643-55.
5. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M, Yamanaka S. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 2003; 113:631-42.
6. Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E, Xu Y. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol advance online publication, 2004; doi:10.1038/ncb1211.
7. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res 2000; 60:6788-93.
8. Ko LJ, Prives C. p53: Puzzle and paradigm. Genes Dev 1996; 10:1054-72.
9. Corbet SW, Clarke AR, Gledhill S, Wyllie AH. P53-dependent and -independent links between DNA-damage, apoptosis and mutation frequency in ES cells. Oncogene 1999; 18:1537-44.
10. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH, Levine AJ. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 2000; 14:981-93.
11. Murphy ME. The thousand doors that lead to death: p53-dependent repression and apoptosis. Cancer Biol Ther 2003; 2:381-2.
12. Hatano SY, Tada M, Kimura H, Yamaguchi S, Kono T, Nakano T, Suemori H, Nakatsuji N, Tada T. Pluripotential competence of cells associated with Nanog activity. Mech Dev 2005; 122:67-79.
13. Chao C, Saito S, Anderson CW, Appella E, Xu Y. Phosphorylation of murine p53 at ser-18 regulates the p53 responses to DNA damage. Proc Natl Acad Sci USA 2000; 97:11936-41.
14. Xu Y. Regulation of p53 responses by post-translational modifications. Cell Death Differ 2003; 10:400-3.
15. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004; 432:324-31.
16. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002; 3:179-98.
17. Sperr WR, Hauswirth AW, Florian S, Ohler L, Geissler K. Valent P. Human leukaemic stem cells: A novel target of therapy. Eur J Clin Invest 2004; 2:31-40.